Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Angiodynamics (ANGO) Restructuring Costs (2016 - 2025)

Angiodynamics (ANGO) has disclosed Restructuring Costs for 14 consecutive years, with $3.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Restructuring Costs fell 38.05% year-over-year to $3.6 million, compared with a TTM value of $31.6 million through Nov 2025, down 16.71%, and an annual FY2024 reading of $53.2 million, up 240.19% over the prior year.
  • Restructuring Costs was $3.6 million for Q4 2025 at Angiodynamics, up from $2.8 million in the prior quarter.
  • Across five years, Restructuring Costs topped out at $19.3 million in Q1 2024 and bottomed at $610000.0 in Q1 2021.
  • Average Restructuring Costs over 5 years is $6.1 million, with a median of $3.6 million recorded in 2023.
  • The sharpest move saw Restructuring Costs soared 1024.02% in 2021, then crashed 88.41% in 2022.
  • Year by year, Restructuring Costs stood at $2.3 million in 2021, then skyrocketed by 35.77% to $3.1 million in 2022, then skyrocketed by 102.29% to $6.2 million in 2023, then dropped by 5.17% to $5.9 million in 2024, then plummeted by 38.05% to $3.6 million in 2025.
  • Business Quant data shows Restructuring Costs for ANGO at $3.6 million in Q4 2025, $2.8 million in Q3 2025, and $19.3 million in Q1 2025.